Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin-like Transcript 3 (ILT3)
- Target
- ILT3
- Molecular classification
- Type I transmembrane protein, Leukocyte Immunoglobulin-like Receptor (LIR), Inhibitory receptor
01
Overview
Immunoglobulin-like Transcript 3 (ILT3), also known as LILRB4, is an inhibitory immune checkpoint receptor expressed predominantly on myeloid lineage cells. It functions to suppress immune responses by recruiting phosphatases to its ITIM motifs upon ligand binding, leading to reduced immune cell activation. In cancer, ILT3 contributes to tumor-mediated immune evasion, making it a target for immunotherapy.
- Other names
- LILRB4CD85kLIR-5
02
Mechanism of action
Inhibition of immune cell activation via recruitment of phosphatases through ITIM motifs, leading to downregulation of immune responses.
03
Biological functions
Immune regulationImmune suppressionInduction of immune toleranceAntigen presentation
04
Disease associations
CancerImmunosuppressionAcute Myeloid Leukemia (AML)
05
Safety considerations
Potential for broad immunosuppressionOff-target effects on myeloid cells
06
Biomarkers
LILRB4 expression on tumor-infiltrating myeloid cells (MDSCs, macrophages)
Beyond the preview
Go deeper on Immunoglobulin-like Transcript 3 (ILT3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin-like Transcript 3 (ILT3).